General principles
The term 'chronic hepatitis' is conventionally restricted to those chronic liver diseases which are due to viral hepatitis or of unknown aetiology (Popper & Schaffner 1976) . This review will deal with the characteristics of chronic hepatitis (in its conventional sense) in the categories developed from histopathological observations.
While not dealt with in this review, the importance of drugs as a cause of chronic hepatitis cannot be overemphasized in view of the usually dramatic improvement when the offending drug is removed. Other treatable causes of chronic hepatitis such as Wilson's disease should also be sought in the initial diagnostic evaluation of the patient with chronic liver disease.
Chronic hepatitis became widely recognized as a clinical entity about thirty years ago, following the adoption of percutaneous liver biopsy as a routine technique. Since that time the development of serum 'liver function tests', and in particular the use of computerized multichannel biochemical analysers, has led to the recognition that chronic hepatitis is a group of diseases with a broad spectrum of severity and several aetiological factors.
Diagnosis
Chronic hepatitis is defined by the histopathological presence of inflammatory changes continuing without improvement for six months or longer. Two forms were initially recognized, chronic persistent hepatitis and chronic active hepatitis, with piecemeal necrosis as the principal distinguishing feature (de Groote et al. 1968) . A third form, chronic lobular hepatitis, has since gained prominence and is included in other classifications (International Group 1977) . Chronic lobular hepatitis can be clearly distinguished from both chronic persistent and chronic active (Scheuer 1977) , and it may be that the degree of lobular inflammation is a better guide to prognosis than is piecemeal necrosis (Popper 1983) .
At present these forms can be identified with certainty only by histological appearances. Clinical and biochemical features show considerable overlap. Percutaneous liver biopsy at best provides a tiny core of liver for examination. A specimen at least 20 mm in length and containing 3 portal tracts is required. Sampling error is a problem in interpretation, particularly in distinguishing between forms of chronic hepatitis, and in establishing the presence of cirrhosis. Three cores of liver usually provide a correct diagnosis and multiple needle passes have been recommended (Abdi et al. 1979) but not routinely adopted. Another problem is observer variation, particularly with histopathologists not specializing in liver biopsy interpretation (Theodossi et al. 1980 ).
Aetiological agents
The scope of this review is limited to chronic hepatitis due to viral hepatitis or of unknown aetiology. It is accepted that viral hepatitis type A rarely, if ever, causes chronic hepatitis.
Hepatitis type B is a major health problem throughout the world, and the most common cause of chronic hepatitis (Hoofnagle 1983) . The hepatitis B virus (HBV) may also be found in asymptomatic carriers with normal liver function tests and liver histology, but these carriers have a substantial mortality due to hepatocellular carcinoma.
The delta agent was first reported in 1977 (for review see Rizzetto 1983) . It is a defective virus, requiring the presence of HBV to replicate. Human delta infection thus occurs only in 'Accepted 15 January 1985 the presence of HBV infection. Its importance lies in the fact that the liver disease in patients infected with delta agent is more severe than HBV infection without delta. This applies both to acute hepatitis (Govindarajan et al. 1984 ) and chronic hepatitis (Raimondo et al. 1983 ). In chronic hepatitis B surface antigen (HBsAg) carriers, cases of acute hepatitis or progression from chronic persistent to chronic active hepatitis, which were previously attributed to non-A, non-B hepatitis, are due to infection with the delta agent (Moestrup et al. 1983) .
Typical viral hepatitis may occur without serological markers of known viruses. This is labelled non-A, non-B (NANB) hepatitis. Many tests for NANB infection have been described but none has proved valuable for general use (Feinstone & Hoofnagle 1984 ). It appears likely on epidemiological grounds that there are several distinct NANB viruses, but a recent paper suggests that a single retrovirus may be responsible (Seto et al. 1984) . NANB hepatitis frequently becomes chronic. In the absence of markers specific to NANB hepatitis, the best documentation comes from post-transfusional hepatitis. In a prospective study Berman et al. (1979) found that 26 of 388 patients undergoing open-heart surgery subsequently developed NANB hepatitis; 12 of these 26 had abnormal serum transaminase levels for more than one year. Another study documented progression to chronic hepatitis in 13 of 21 similar patients (Realdi et al. 1982) . Sporadic NANB hepatitis also becomes chronic. Chronicity developed in 9 of 12 patients in one study (Bamber et al. 1981) . Other workers have reported that the transition to chronic hepatitis occurs in about 20% of cases, and that the liver disease in these cases is usually mild (Rakela & Redeker 1979) .
Many patients with chronic hepatitis give no history of clinical acute viral hepatitis, and have no serological markers of HBV infection. These idiopathic cases comprise a small proportion of the chronic persistent and chronic lobular hepatitis groups, but a larger proportion of the chronic active hepatitis group. It is likely that some cases are due to chronic NANB infection, while others are of the type called 'autoimmune'. Unfortunately the definition of 'autoimmune' chronic active hepatitis is unclear. Presence in serum of nonspecific tissue antibodies such as antinuclear factor (ANF) and antismooth muscle antibody (SMA) is usually used (Mackay 1983 ). These antibodies also occur in some cases of HBV-associated and posttransfusional NANB disease. There is a genetic predisposition to 'autoimmune' chronic active hepatitis, with patients carrying the HLA-B8 and DR3 haplotypes being at increased risk (Whittingham et al. 1981) . Recently, antigen-specific suppressor cell function has been shown to be depressed (Vento et al. 1984 ) and liver membrane binding antibodies are present (Wiedmann et al. 1984) . Both these abnormalities are said to occur in 'autoimmune' but not in HBV-associated chronic active hepatitis. This author dislikes the term autoimmune, but a satisfactory alternative does not exist. Chronic active hepatitis due to all causes is autoimmune in the sense that host cells cause the hepatocellular injury (Thomas & Lok 1984) .
Chronic persistent hepatitis Pathology: Chronic persistent hepatitis (CPH) is characterized by the enlargement of portal tracts due to infiltration by mononuclear cells. The limiting plate of hepatocytes remains intact. In the lobules, spill-over of inflammatory cells may occur in periportal areas, and there may be scattered foci of inflammation and hepatocyte necrosis. The lobular architecture is preserved, although there may be portal fibrosis or fibrous septa radiating from portal tracts.
This histopathology may occur in other disease entities such as primary biliary cirrhosis, and is not in itself sufficient to diagnose CPH. Clinical and laboratory features must also be taken into account. In patients with chronic active hepatitis on corticosteroid or other therapy, the histological appearances may be that of CPH. This state does not have as good a prognosis as 'primary' CPH, since the disease may overtly relapse to chronic active hepatitis, and progression to cirrhosis without clinical relapse also occurs (Czaja et al. 1981 a) .
Aetiology: A consecutive series of 53 patients with CPH in Copenhagen included 25 HBsAgpositive patients of whom 16 were also hepatitis B e antigen (HBeAg) positive (Aldershvile et al. 1982) . In a group of 59 patients with HBV-associated chronic liver disease there were 9 CPH cases (Dudley et al. 1972) . Delta antigen was detected in none of 9 HBsAG-positive patients with CPH (Weller et al. 1983) .
Only one of 13 cases of post-transfusional chronic NANB hepatitis was morphologically CPH (Realdi et al. 1982) . One of 6 cases of sporadic chronic NANB hepatitis was CPH (Bamber et al. 1981) .
Clinical: Patients with CPH are usually asymptomatic. Minor symptoms such as lethargy may be present, and specific symptoms attributable to the aetiological agent may also occur. The onset is usually insidious, but in some series more than half the cases of CPH originated in an illness suggestive of acute viral hepatitis (Becker et al. 1970) . Hepatomegaly is present in about half the cases. Other abnormal physical signs are not usually found.
Laboratory: The serum levels of aspartate aminotransferase (AsT) and alanine aminotransferase (AlT) are usually elevated, although intermittently normal levels may be recorded. Serum unconjugated bilirubin levels may be elevated mimicking Gilbert's sytidrome. This is due to depressed hepatic activity of bilirubin UDP-glucuronyltransferase (Felsher & Carpio 1979) . Other tests of liver function are usually normal.
Course: CPH is generally regarded as benign. Some patients develop the appearances of chronic lobular hepatitis (Dudley et al. 1972) or chronic active hepatitis without cirrhosis (Chadwick et al. 1979) . One patient is reported to have developed cirrhosis seven months after an initial biopsy showed the appearances of CPH (Dietrichson 1975) . In HBV-associated CPH, subjects who remain HBeAg-positive during follow up may develop cirrhosis and do not show histological or biochemical improvement (Aldershvile et al. 1982) . This paper used a broad definition of CPH (de Groote et al. 1968 ). Seroconversion from HBeAg-positive to anti-HBe-positive is preceded by elevation of transaminases, and perhaps the worsening of lobular inflammation histologically, but is followed by resolution of the illness and development of a healthy HBsAg carrier state (Sanchez-Tapias et al. 1984) . Unfortunately relapse to the HBeAg-positive state and reactivation of liver disease may occur . With the exception of HBeAg, no features at presentation have been identified as reliable markers of prognosis.
Chronic lobular hepatitis Pathology: Chronic lobular hepatitis (CLH) is characterized histopathologically by lobular changes of spotty necrosis and inflammatory infiltration, similar in pattern to acute hepatitis. There may be widespread hepatocyte swelling with frequent apoptotic bodies, and Kupffer cells enlarged and containing pigment (Popper & Schaffner 1976) . Portal tracts usually show a chronic inflammatory infiltrate, but this may be mild. Piecemeal necrosis is absent. CLH must be distinguished from chronic active hepatitis with a prominent lobular inflammatory component (Scheuer 1977) , which would be expected to have a worse prognosis.
Aetiology: Serological markers of HBV infection were detected in 54 of 80 patients from Taiwan (Liaw et al. 1982 ), but may be less frequent in Western series. Only one of 59 patients with HBV-associated chronic liver disease had CLH (Dudley et al. 1972) . Six of 17 drug addicts with HBV-associated lobular hepatitis (chronicity uncertain) were found to be infected by the delta agent (Raimondo et al. 1982) .
Two of 21 patients with post-transfusional acute NANB hepatitis went on to develop CLH (Realdi et al. 1982) . Three of 12 cases of sporadic NANB hepatitis developed CLH (Bamber et al.. 1981) . In the Taiwan series 11 of 80 cases of CLH were ascribed to post-transfusional NANB (Liaw et al. 1982) .
Clinical: The onset may be similar to acute hepatitis. In some patients relapses mimicking acute hepatitis occur (Wilkinson et al. 1978) . In others, the clinical picture is similar to that of CPH. In addition to hepatomegaly, splenomegaly may be present, and spider naevi are occasionally seen (Liaw et al. 1982) .
Laboratory: Serum aminotransferase levels are increased. Nonspecific tissue antibodies may become detectable in the serum (Wilkinson et al. 1978) . Serum alkaline phosphatase, bilirubin and globulin levels are frequently elevated, but albumin levels are usually normal (Liaw et al. 1982) . As with the clinical course, the biochemical abnormality fluctuates over time.
Course: Some patients with recurrent symptomatic episodes require, and appear to respond to, steroids (Wilkinson et al. 1978) . The nature of the disease makes evaluation of the, response to therapy difficult. Progression to cirrhosis is rare.
Chronic active hepatitis Pathology: Piecemeal necrosis is the hallmark of chronic active hepatitis (CAH). Piecemeal necrosis is the inflammatory destruction of small groups of liver cells in periportal or periseptal areas by lymphocytes and macrophages which are in close contact with the hepatocytes (Bianchi 1983) .
Bridging necrosis is an important feature of CAH. Portal-portal linkage (sometimes misnamed bridging) is best regarded as an extension of piecemeal necrosis (International Group 1977) . On the other hand, central-portal and central-central bridging is indicative of confluent necrosis. In acute hepatitis bridging necrosis does not reliably predict progression to chronic liver disease, but in chronic hepatitis it may predict the later development of cirrhosis (Baggenstoss et al. 1972 ). However, another study (Dietrichson & Christoffersen 1977) found that severe periportal inflammation (portal-portal linkage), but not bridging necrosis, predicted the later development of cirrhosis. A further study (Okuno et al. 1983 ) grouped portal-portal linkage with central-portal and central-central bridging, and found a strong positive correlation with the later development of cirrhosis.
It seems best to regard CAH and cirrhosis as separate but interrelated processes and to use the description 'CAH (with or without cirrhosis)' (Scheuer 1977) .
Aetiology: Thirty years ago, chronic active hepatitis was thought to be a disease affecting females at the beginning and end of their reproductive life and, although perhaps secondary to infection (Saint et al. 1953) , primarily due to disturbed immunity and linked to disseminated lupus erythematosus (Mackay et al. 1956 ). This concept remained prevalent, and when the three controlled trials of immunosuppressive therapy were commenced in the period 1963-1968, they were aimed at this 'autoimmune' type of CAH. The controlled trials established that corticosteroid therapy is effective in reducing mortality of patients with severe symptomatic CAH (Wright et al. 1977) . For reasons that are unclear, 'autoimmune' CAH is decreasing in frequency, even in Australia (Bradbear et al. 1984) , the country of its original description. In England (Hodges et al.. 1982) and California (Koretz et al. 1980) it is very uncommon.
In a retrospective study of 1154 patients with biopsy-proven CAH from Italy (Giusti et al. 1983) , HBsAg was present in the serum of 700 (61%). Of the HBsAG-negative cases, 130 (29%) gave a history of 'hepatitis-like' jaundice. A study from England (Hodges et al. 1982) found 61 newly-diagnosed cases of CAH over a five-year period in a population of 400 000. This study included 2 cases secondary to drugs, 16 alcohol-related and 8 due to alpha-lantitrypsin deficiency, which would be excluded by the conventional definition of chronic hepatitis used here. Of the remaining 35 cases, 12 subjects were HBsAg-positive in serum, and a further 9 were attributed to NANB hepatitis. In a retrospective study from Los Angeles, Koretz et al. (1980) traced 40 patients with histologically proven CAH who might be considered for corticosteroid therapy. In this group, 15 were HBsAg-positive and a further 13 were considered to be due to NANB hepatitis. The authors concluded that no patient over a five-year period in their institution met the currently accepted criteria for corticosteroid therapy.
Clinical: Up to one-third of patients may be asymptomatic at presentation. Males predominate in the HBV-associated group, and females in the remainder. Associated diseases of disordered immunity are common in the HBsAg-negative group. Hepatomegaly is present in 80% and splenomegaly in 40% (Giusti et al. 1983) . About 10% of subjects are jaundiced at presentation.
Laboratory: The AsT is usually elevated. Levels may be ten times the upper limit of normal (ULN), but are more frequently in the range of three to five times ULN. Other biochemical abnormalities depend largely on the aetiology and stage of the disease. During and after therapy, normal laboratory studies occur even in the presence of hepatocellular inflammation and necrosis (Czaja et al. 198 lb).
Course. The earliest studies of CAH showed a mortality of about 50% in two years (Saint et al. 1953 ). This would not be representative of current experience, although there remains a substantial mortality, particularly in the HBV-associated group (Bradbear et al. 1984) . In severe HBsAg-negative CAH, corticosteroid therapy is indicated. It reduces the mortality and may prevent the development of cirrhosis (Wright et al. 1977) . In the Mayo Clinic study, 18 of 83 patients with precirrhotic HBsAg-negative CAH reverted to normal liver histology on corticosteroid therapy, although 5 relapsed following treatment withdrawal (Czaja et al. 1984) . In HBsAg-positive CAH, corticosteroid therapy may be harmful . Antiviral therapy for these cases is promising, but remains a research procedure at present (Schalm 1984) . No therapy is available for delta-associated CAH; retrospective studies have demonstrated that corticosteroids are ineffective, and levamisole has produced no benefit (Rizzetto 1983) . NANB CAH may progress to cirrhosis (Realdi et al. 1982) but is usually thought to be a mild disease (Berman et al. 1979 ) compared with other types of CAH. Trials of therapy are hampered by the lack of a specific disease marker.
